Key Points
CBDL stock surged 40% with 233M shares traded on PNK exchange
Company shows strong balance sheet with zero debt and 15.12 current ratio
Meyka AI rates CBDL as B-grade HOLD despite unprofitable operations
Technical indicators signal overbought conditions with MFI at 88.61
CBDL stock surged 40% today on the PNK exchange, trading at $0.00035 USD with exceptional volume. CBD Life Sciences Inc., a Scottsdale-based cannabidiol product manufacturer, saw 233 million shares change hands during regular market hours. The company develops hemp drops, massage oils, pain relief creams, and pet products. This dramatic price movement reflects heightened investor interest in the micro-cap healthcare stock. Trading volume reached 5.3 times the average daily volume, signaling significant market activity.
CBDL Stock Price Action and Trading Volume
CBDL stock opened at $0.0002 and climbed to a daily high of $0.0004, closing near the top of its range. The 40% gain represents the strongest single-day performance in recent trading. Volume exploded to 233.4 million shares, dwarfing the typical daily average of 16.9 million shares.
The stock trades well below its 52-week high of $0.001 but above its 52-week low of $0.0001. Market cap stands at approximately $563,091 USD with 1.88 billion shares outstanding. This micro-cap positioning means price swings can be dramatic on modest trading activity.
CBDL Stock Valuation and Financial Metrics
Meyka AI rates CBDL with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
The company shows a price-to-sales ratio of 12.73 and price-to-book ratio of 1.61. CBDL carries zero debt with a strong current ratio of 15.12, indicating solid short-term liquidity. However, the stock trades at a negative PE ratio of -204.92 due to recent losses. Track CBDL on Meyka for real-time updates on valuation shifts.
Market Sentiment and Technical Indicators
Trading Activity: CBDL’s relative volume reached 5.31, showing exceptional investor participation. The RSI of 58.10 suggests neutral momentum, while the ADX of 58.84 indicates a strong underlying trend. The CCI reading of 166.93 signals overbought conditions, warning of potential pullback risk.
Liquidation: The Money Flow Index (MFI) of 88.61 confirms overbought status across volume-weighted price movements. The Stochastic %K of 63.89 and %D of 64.63 suggest momentum may be peaking. Investors should monitor whether this surge sustains or reverses in coming sessions.
CBDL Stock Performance and Long-Term Outlook
CBDL has climbed 250% over one month and 75% year-to-date, though it remains down 99.99% from all-time highs. The company operates in the healthcare sector, specifically drug manufacturing for specialty cannabidiol products. CEO Lisa Anne Nelson leads a lean team of 3 full-time employees from Scottsdale, Arizona.
The company generated minimal revenue with negative earnings, reflecting early-stage operations. Despite challenges, the zero-debt balance sheet and strong cash position provide runway for product development. Long-term viability depends on scaling CBD product sales and achieving profitability.
Final Thoughts
CBDL stock delivered a 40% single-day surge on massive trading volume, capturing attention in the micro-cap healthcare space. The 233 million shares traded demonstrate strong retail interest in CBD Life Sciences Inc. However, investors must recognize the company’s unprofitable status and minimal revenue base. The B-grade rating from Meyka AI suggests holding rather than aggressive buying. Technical indicators show overbought conditions, signaling caution for new entrants. This remains a speculative play suitable only for risk-tolerant traders monitoring the cannabidiol sector closely.
FAQs
CBDL surged on exceptional trading volume of 233 million shares, 5.3 times average. The micro-cap nature means modest buying pressure creates large percentage moves, likely driven by retail momentum trading rather than company news.
Meyka AI rates CBDL as HOLD with a B grade. The unprofitable company has minimal revenue but maintains a strong balance sheet with zero debt. Execution risk remains high for this early-stage CBD manufacturer.
CBDL develops and markets cannabidiol-based organic products including hemp drops, massage oils, pain relief creams, anxiety supplements, edibles, and pet products from its Scottsdale headquarters with three full-time employees.
MFI of 88.61 and CCI of 166.93 signal overbought conditions. Stochastic indicators suggest momentum may be peaking, typically preceding pullbacks or consolidation in micro-cap stocks.
CBDL trades at $0.00035, between its 52-week low of $0.0001 and high of $0.001. The stock is down 99.99% from all-time highs but up 250% over the past month, showing extreme volatility.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)